CRO and Biotech Discuss Advancements in Radiotherapy
In a recent webinar, Medpace Radiation Oncologist, Radiation Clinical Pharmacologist, was joined by a biotech Molecular Imaging Director, and Academic Medical Physicist to cover considerations in alpha-particle therapy.
While alpha emitter isotope therapy, radium, has been available for over a hundred years, there is renewed promise for targeted alpha therapy in treating advanced and metastatic tumors. There are recent reports showing impressive safety and tumor response with alpha-particle therapy across many solid tumor populations.
In this webinar, experts reviewed:
- History of alpha emitting radionuclides
- Radiobiologic considerations for Ra-223, Actinium 225, Lead 212
- Concepts for radiation planning and personalized dosimetry
- Optimal approaches for pharmacokinetics
- Medical considerations necessary to design a successful alpha-RPT clinical trial
Accelerating Global Radiation Therapy Clinical Development
Radiopharmaceutical drug development has advanced over the last decade, most notably in the field of imaging and oncology. Our in-house team of radiation oncologists and imaging experts understand the biological, clinical, regulatory, operational, and imaging considerations that must be factored in when designing and executing radiopharmaceutical trials.